{"id":810486,"date":"2025-02-07T08:53:14","date_gmt":"2025-02-07T13:53:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-a-planned-follow-up-clinical-study-evaluating-a-combination-treatment-of-aims-ampligen-and-astrazenecas-flumist-to-address-the-recent-avian-influ\/"},"modified":"2025-02-07T08:53:14","modified_gmt":"2025-02-07T13:53:14","slug":"aim-immunotech-announces-a-planned-follow-up-clinical-study-evaluating-a-combination-treatment-of-aims-ampligen-and-astrazenecas-flumist-to-address-the-recent-avian-influ","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-a-planned-follow-up-clinical-study-evaluating-a-combination-treatment-of-aims-ampligen-and-astrazenecas-flumist-to-address-the-recent-avian-influ\/","title":{"rendered":"AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM\u2019s Ampligen\u00ae and AstraZeneca\u2019s FluMist\u00ae to address the recent avian influenza outbreaks"},"content":{"rendered":"

\nPlanned Investigational New Drug application to expand on previous clinical work at the University of Alabama-Birmingham in which administration of Ampligen as an intranasal adjuvant increased immune response, including cross-protection via avian influenza antibody generation in humans
\n<\/h2>\n
\n

OCALA, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc.<\/a> (NYSE American: AIM)\u00a0<\/strong>(\u201cAIM\u201d or the \u201cCompany\u201d) today announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company\u2019s antiviral priority development pipeline.<\/p>\n

AIM has engaged Amarex Clinical Research (\u201cAmarex\u201d), its Clinical Research Organization (\u201cCRO\u201d), with the application and eventual management of a follow-up Investigational New Drug (\u201cIND\u201d) application for the study of a potential avian influenza combination therapy of AIM\u2019s Ampligen and AstraZeneca\u2019s FluMist, a nasal spray vaccine that helps prevent seasonal influenza. AIM is seeking collaborative grants from government and industry to defray the cost of the study.<\/p>\n

The new proposed clinical trial would expand upon previous Company-sponsored clinical research at the University of Alabama-Birmingham (\u201cUAB\u201d) (Overton 2014<\/a>), which indicated that intranasal delivery of Ampligen after the intranasal delivery of the FluMist seasonal influenza vaccine not only increased the immune response to seasonal variants in the vaccine by greater than four-fold, but most importantly induced cross-reactive secretory Immunoglobulin A against highly pathogenic avian influenza virus strains H5N1, H7N9 and H7N3.<\/p>\n

\n See ClinicalTrials.gov: <\/em>
\n
\n NCT01591473 \u2013 \u201cSafety Study of FluMist With and Without Ampligen\u201d<\/em>
\n <\/a>\n <\/p>\n

AIM CEO Thomas K. Equels stated: \u201cThe avian flu has emerged as a serious and ever-growing public health threat. We believe there is the potential for an influenza vaccination program that provides broader coverage than the currently approved vaccination programs, with the added simplicity of being delivered intranasally. Specifically, there is already both pre-clinical and clinical data which demonstrates potential for synergy between our lead compound Ampligen to provide greater efficacy and potential epitope spreading and cross-reactivity for avian influenza when combined with AstraZeneca\u2019s FluMist vaccine. Based on the UAB clinical data to date, we believe such a combination therapy could also be an effective barrier against avian flu infections.\u201d<\/p>\n

This Company\u2019s belief stems directly from the pre-clinical and clinical work performed with Ampligen and multiple influenza variants, some of which supported the conception of the original UAB study.<\/p>\n